drugset / Trial / NCT00004699
Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Treatment
Summary
OBJECTIVES: I. Determine the dose of recombinant human insulin-like growth factor I that minimizes or decreases the need for exogenous glucose support without causing hypoglycemia.
Timeline
- Start
- 1995-08
- Primary completion
- —
- Completion
- 1999-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mecasermin | Protein / enzyme biologic | — | Subcutaneous |